Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Nuclear mitotic apparatus protein (NuMA) in benign and malignant diseases
Autore:
Hasholzner, U; Stieber, P; Zimmermann, A; Burges, A; Hofmann, K; Schmitt, UM; Schmeller, N; Schalhorn, A;
Indirizzi:
Univ Munich, Klinikum Grosshadern, Inst Klin Chem, D-81366 Munich, GermanyUniv Munich Munich Germany D-81366 st Klin Chem, D-81366 Munich, Germany Univ Munich, Klinikum Grosshadern, Dept Surg, D-81366 Munich, Germany UnivMunich Munich Germany D-81366 n, Dept Surg, D-81366 Munich, Germany Univ Munich, Klinikum Grosshadern, Dept Gynecol, D-81366 Munich, Germany Univ Munich Munich Germany D-81366 Dept Gynecol, D-81366 Munich, Germany Univ Munich, Klinikum Grosshadern, Dept Urol, D-81366 Munich, Germany UnivMunich Munich Germany D-81366 n, Dept Urol, D-81366 Munich, Germany Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, D-81366 Munich, Germany Univ Munich Munich Germany D-81366 ternal Med 3, D-81366 Munich, Germany
Titolo Testata:
ANTICANCER RESEARCH
fascicolo: 4A, volume: 19, anno: 1999,
pagine: 2415 - 2420
SICI:
0250-7005(199907/08)19:4A<2415:NMAP(I>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
MATRIX PROTEINS; CANCER;
Keywords:
tumour marker; colorectal cancer; nuclear matrix protein; nuclear mitotic apparatus protein NuMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
11
Recensione:
Indirizzi per estratti:
Indirizzo: Hasholzner, U Univ Munich, Klinikum Grosshadern, Inst Klin Chem, Marchioninistr 15, D-81366 Munich, Germany Univ Munich Marchioninistr 15 Munich Germany D-81366 ermany
Citazione:
U. Hasholzner et al., "Nuclear mitotic apparatus protein (NuMA) in benign and malignant diseases", ANTICANC R, 19(4A), 1999, pp. 2415-2420

Abstract

Nuclear mitotic apparatus protein (NuMA) is a 239 kDa internal nuclear matrix protein described to be elevated in cancer patients especially in colorectal carcinoma and early colorectal cancers. We tested the significance ofNuMA as tumour marker in colorectal cancer and also the sensitivity / specificity profile in general. Therefore, we investigated in a retrospective clinical study 507 sera from patients suffering from solid tumours, with themain emphasis on colorectal carcinoma, and 418 sera from patients with benign diseases and healthy individuals. Testing was done with a double monoclonal enzyme immunoassay detecting head and rod domain of NuMA and results were compared to the established tumour associated antigens. Based on a specificity of 95% versus the benign reference group of gastrointestinal diseases, we found - at the time of primary diagnosis - a sensitivity for colorectal cancer of 8 % for NuMA, 36 % for CEA and 17 % for CA 19-9. Regarding T-stages of colorectal cancer no marker detected :T1 when regarding 95 % specificity-cut-off value but NuMA showed little more sensitivity when based ona 95 % specificity cut off value versus healthy. This could not be shown in Dukes' stages. Regarding all other solid tumours tested - all based on a specificity of 95 % for the corresponding benign reference groups - no advantage of NuMA in sensitivity for all other solid tumours investigated was found. No additional sensitivity could be observed Based on our results, theNuMA-assay in its present form has no clinical relevance.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/09/20 alle ore 11:14:50